Pediatric Weight Loss: GLP-1 Prescriptions Rise for Children

Baton Rouge physicians are increasingly prescribing GLP-1 weight-loss drugs to children, a trend driven by cases where lifestyle changes alone do not reverse obesity. Dr. Rhea Rogers, a board-certified physician and host of the program Aging Untold, explained that genetics and hormonal dysregulation often limit the effectiveness of standard advice to move more and eat less.

Rogers stated that when a child becomes significantly overweight, the body enters a state of hormonal imbalance. In these cases, GLP-1 agonists serve as a medical tool to address the underlying physiology. She described the medication as effective for reducing what she calls "food noise" and "food chatter," while also noting its anti-inflammatory properties.

The push for medical intervention follows a statewide effort to lower obesity rates in Louisiana. At Magnolia Woods Elementary in Baton Rouge, students participate in programs designed to teach healthy eating habits and exercise. These educational initiatives form the first line of defense, but medical professionals acknowledge that they are not sufficient for every patient.

Eligibility criteria for pediatric GLP-1 use are specific. For patients diagnosed with diabetes, the age requirement starts at 10 years old. For those seeking treatment specifically for weight loss, experts identify the ideal candidate as having a Body Mass Index at or above the 95th percentile. Additionally, the child must have failed to lose weight through lifestyle modifications alone, or must have developed hormone problems that require medical intervention.

Rogers emphasized that the medication is not a miracle cure but rather one component of a comprehensive treatment plan. "It’s not a miracle drug, it’s a tool, and so you have to treat the whole entire scenario," she said. This approach requires doctors to manage the full medical picture rather than focusing solely on the prescription.

Cost remains the primary obstacle for many families considering this treatment. For patients who cannot afford the medication or choose not to take it, the current standard of care remains a well-balanced diet and an active lifestyle. The financial burden continues to dictate which children receive pharmacological support versus behavioral management.

The shift toward prescribing these drugs to minors marks a change in pediatric care for obesity. While the medication has been a staple in adult weight-loss clinics for some time, its application in younger populations is growing. Doctors are now viewing it as a necessary option for specific cases where biological factors outweigh behavioral ones.